<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1274201</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>DNase improves the efficacy of antimicrobial photodynamic therapy in the treatment of candidiasis induced with <italic>Candida albicans</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Jord&#x00E3;o</surname> <given-names>Cl&#x00E1;udia Carolina</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/886095/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Klein</surname> <given-names>Marlise In&#x00EA;z</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/199773/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Barbugli</surname> <given-names>Paula Aboud</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1106452/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mima</surname> <given-names>Ewerton Garcia de Oliveira</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/825783/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>de Sousa</surname> <given-names>T&#x00E1;bata Viana</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ferrisse</surname> <given-names>T&#x00FA;lio Morandin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1932182/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Pavarina</surname> <given-names>Ana Claudia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/826176/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratory of Applied Microbiology, Department of Dental Materials and Prosthodontics, School of Dentistry, S&#x00E3;o Paulo State University (UNESP)</institution>, <addr-line>Araraquara</addr-line>, <country>Brazil</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Oral Diagnosis, Piracicaba Dental School, State University of Campinas (UNICAMP)</institution>, <addr-line>Piracicaba</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: Ana R. Freitas, Cooperativa de Ensino Superior Polit&#x00E9;cnico e Universit&#x00E1;rio, Portugal</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: Shakir Khan, Harvard Medical School, United States; Celia Fortuna R., Cooperativa de Ensino Superior Polit&#x00E9;cnico e Universit&#x00E1;rio, Portugal</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Ana Claudia Pavarina, <email>ana.pavarina@unesp.br</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1274201</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>08</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>12</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Jord&#x00E3;o, Klein, Barbugli, Mima, de Sousa, Ferrisse and Pavarina.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Jord&#x00E3;o, Klein, Barbugli, Mima, de Sousa, Ferrisse and Pavarina</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The study evaluated the association of DNase I enzyme with antimicrobial photodynamic therapy (aPDT) in the treatment of oral candidiasis in mice infected with fluconazole-susceptible (CaS) and -resistant (CaR) <italic>Candida albicans</italic> strains. Mice were inoculated with <italic>C. albicans</italic>, and after the infection had been established, the tongues were exposed to DNase for 5&#x2009;min, followed by photosensitizer [Photodithazine<sup>&#x00AE;</sup>(PDZ)] and light (LED), either singly or combined. The treatments were performed for 5 consecutive days. Treatment efficacy was evaluated by assessing the tongues via fungal viable population, clinical evaluation, histopathological and fluorescence microscopy methods immediately after finishing treatments, and 7&#x2009;days of follow-up. The combination of DNase with PDZ-aPDT reduced the fungal viability in mice tongues immediately after the treatments by around 4.26 and 2.89 log<sub>10</sub> for CaS and CaR, respectively (versus animals only inoculated). In the fluorescence microscopy, the polysaccharides produced by <italic>C. albicans</italic> and fungal cells were less labeled in animals treated with the combination of DNase with PDZ-aPDT, similar to the healthy animals. After 7&#x2009;days of the treatment, DNase associated with PDZ-aPDT maintained a lower count, but not as pronounced as immediately after the intervention. For both strains, mice treated with the combination of DNase with PDZ-aPDT showed remission of oral lesions and mild inflammatory infiltrate in both periods assessed, while animals treated only with PDZ-aPDT presented partial remission of oral lesions. DNase I enzyme improved the efficacy of photodynamic treatment.</p>
</abstract>
<kwd-group>
<kwd>photochemotherapy</kwd>
<kwd>
<italic>Candida albicans</italic>
</kwd>
<kwd>antifungal drug resistance</kwd>
<kwd>fungi</kwd>
<kwd>enzyme</kwd>
</kwd-group>
<counts>
<fig-count count="13"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="40"/>
<page-count count="15"/>
<word-count count="7987"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antimicrobials, Resistance and Chemotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Oropharyngeal candidiasis (OPC) is the most prevalent infection caused by <italic>Candida</italic> spp. (<xref ref-type="bibr" rid="ref2">Akpan and Morgan, 2002</xref>; <xref ref-type="bibr" rid="ref13">Eggimman et al., 2003</xref>). Infections caused by <italic>Candida</italic> spp. are associated with biofilm formation, a complex microstructure of cells adhered to a surface and enveloped by an extracellular matrix (ECM) (<xref ref-type="bibr" rid="ref16">Flemming et al., 2007</xref>). ECM contributes to preserving biofilms and conserving stable interactions between cells, surfaces (substrate), and the environment (<xref ref-type="bibr" rid="ref16">Flemming et al., 2007</xref>). In addition, ECM reduces the susceptibility of microorganisms against therapies classically used (<xref ref-type="bibr" rid="ref16">Flemming et al., 2007</xref>; <xref ref-type="bibr" rid="ref36">Seneviratne et al., 2008</xref>). Biochemical analyses show that the production of polysaccharides (&#x03B2;-1-3-glucan, &#x03B2;-1-6-glucan, &#x03B2;-1-6-mannan and chitin, for example), nucleic acids (extracellular DNA&#x2014;eDNA) and lipids protect the biofilm&#x2019; cells and keep stable interactions between ECM components (<xref ref-type="bibr" rid="ref13">Eggimman et al., 2003</xref>; <xref ref-type="bibr" rid="ref29">Nett et al., 2007</xref>; <xref ref-type="bibr" rid="ref26">Martins et al., 2010</xref>). The antifungal resistance of <italic>Candida albicans</italic> biofilms is multifactorial, including the stimulation of drug efflux pumps, the physiological state of the cells, and the protection employed by the ECM through &#x03B2;-mannan and &#x03B2;-glucans that bind with fluconazole and amphotericin B (<xref ref-type="bibr" rid="ref16">Flemming et al., 2007</xref>; <xref ref-type="bibr" rid="ref36">Seneviratne et al., 2008</xref>). In addition to &#x03B2;-mannan and &#x03B2;-glucan, eDNA is an important constituent of the ECM and promotes the structural integrity of biofilms (<xref ref-type="bibr" rid="ref27">Mitchell et al., 2016</xref>). The addition of DNase enzyme improves the susceptibility of mature <italic>C. albicans</italic> biofilms against some antifungal agents (<xref ref-type="bibr" rid="ref26">Martins et al., 2010</xref>). Furthermore, the presence of polysaccharides or eDNA was reported as a bacterial biofilm mechanism of protection against the diffusion of antibiotics (<xref ref-type="bibr" rid="ref3">Al-Fattani and Douglas, 2006</xref>; <xref ref-type="bibr" rid="ref5">Anderson and O'Toole, 2008</xref>; <xref ref-type="bibr" rid="ref28">Mulcahy et al., 2008</xref>).</p>
<p>Because the ECM has been related to biofilm protection (<xref ref-type="bibr" rid="ref30">Nobile et al., 2008</xref>), the use of enzymes capable of hydrolyzing polysaccharides and nucleic acids has been investigated, as it represents an alternative way of increasing the susceptibility of the biofilm to antifungal drugs (<xref ref-type="bibr" rid="ref30">Nobile et al., 2008</xref>). DNase I enzyme can significantly reduce eDNA, soluble matrix proteins, and water-soluble polysaccharides of a fluconazole-resistant <italic>C. albicans</italic> (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>). This enzyme acts externally to the cell, reducing biofilm stability and enhancing its susceptibility to photodynamic therapy and antifungals (<xref ref-type="bibr" rid="ref22">Liao, 1974</xref>; <xref ref-type="bibr" rid="ref25">Martins et al., 2012</xref>; <xref ref-type="bibr" rid="ref38">Tetz and Tetz, 2016</xref>; <xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>). The treatment of mature biofilms with DNase I (50&#x2009;mg/mL) inhibited adhesion, biofilm formation, and reduced the biomass by approximately 30% (<xref ref-type="bibr" rid="ref32">Perezous et al., 2005</xref>). Incubation of <italic>in vitro</italic> 48&#x2009;h-old biofilms for 5&#x2009;min to DNase I reduced eDNA and extracellular polysaccharides in the ECM of fluconazole-susceptible and -resistant <italic>C. albicans</italic> strains (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>).</p>
<p>Due to the increase of resistant microorganisms (<xref ref-type="bibr" rid="ref20">Kumar et al., 2022</xref>), the side effects of antifungals (<xref ref-type="bibr" rid="ref7">Campoy and Adrio, 2017</xref>), recolonization, and organization into biofilms (<xref ref-type="bibr" rid="ref20">Kumar et al., 2022</xref>), studies have evaluated alternative strategies to manage fungal infections. In this context, antimicrobial photodynamic therapy (aPDT) is suggested for inactivating microorganisms and treating oral candidiasis (<xref ref-type="bibr" rid="ref21">Lambrechts et al., 2005</xref>; <xref ref-type="bibr" rid="ref19">Konopka and Goslinski, 2007</xref>; <xref ref-type="bibr" rid="ref12">Donnelly et al., 2008</xref>). The photodynamic process requires a photosensitizing agent (PS) combined with light with a wavelength corresponding to the PS absorption band (<xref ref-type="bibr" rid="ref12">Donnelly et al., 2008</xref>). The interaction of light with PS, in the presence of oxygen, produces reactive species capable of inducing cell inactivation (<xref ref-type="bibr" rid="ref24">Machado, 2000</xref>). Reactive species have non-specific reactivity with organic molecules and can cause irreversible damage to cellular targets, such as membrane lysis and protein inactivation. Thus, any cellular macromolecule can be considered a target for aPDT (<xref ref-type="bibr" rid="ref6">Bonnett and Mart&#x00ED;nez, 2001</xref>; <xref ref-type="bibr" rid="ref12">Donnelly et al., 2008</xref>).</p>
<p>Photodithazine (PDZ)-aPDT inactivated <italic>Candida</italic> biofilms and treated oral candidiasis (<xref ref-type="bibr" rid="ref36">Seneviratne et al., 2008</xref>; <xref ref-type="bibr" rid="ref26">Martins et al., 2010</xref>). A single application of PDZ-aPDT in a murine model decreased the fluconazole-susceptible <italic>C. albicans</italic> (ATCC 90028) viability by 4.36 log<sub>10</sub> (<xref ref-type="bibr" rid="ref9">Carmello et al., 2015</xref>). On the other hand, mice infected by a fluconazole-resistant <italic>C. albicans</italic> strain (ATCC 96901) that received a single session of PDZ-aPDT presented reduced fungal cell viability by 1.96 log<sub>10</sub> (<xref ref-type="bibr" rid="ref4">Alves et al., 2018</xref>). Five consecutive applications of PDZ-aPDT or antifungal nystatin promoted reductions in the fluconazole-susceptible <italic>C. albicans</italic> (ATCC 90028) by 3 and 3.2 logs<sub>10</sub>, respectively, and yielded the remission of tongue lesions after 24&#x2009;h of treatment (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>). When the animals were inoculated with a fluconazole-resistant strain (ATCC 96901), PDZ-aPDT was as effective as the topical antifungal nystatin in the treatment, reducing viability by around 1.2 log<sub>10</sub> (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>); however, the animals showed white or pseudomembranous patches on the dorsum of the tongues. In animals inoculated with fluconazole-resistant <italic>C. albicans</italic>, the associations of treatments (PDZ-aPDT and nystatin) reduced ~2.3 log<sub>10</sub> of fluconazole-resistant <italic>C. albicans</italic> (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>), and the macroscopic analysis revealed remission of oral lesions ranging ~95% after 24&#x2009;h (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). In general, previous studies (<xref ref-type="bibr" rid="ref9">Carmello et al., 2015</xref>, <xref ref-type="bibr" rid="ref8">2016</xref>; <xref ref-type="bibr" rid="ref4">Alves et al., 2018</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>) demonstrated the efficacy of PDZ-aPDT in treating infections caused by fluconazole-susceptible <italic>C. albicans</italic>. However, fluconazole-resistant <italic>C. albicans</italic> have reduced susceptibility to aPDT, and to find similar outcomes in the treatment of infections with these strains, it is necessary to combine treatments.</p>
<p>DNase treatment might be an adjuvant to anti-biofilm therapies since it reduces most ECM components that can hinder antifungal drug penetration into biofilms without interfering with cell viability (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>; <xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). The incubation of fluconazole-susceptible <italic>C. albicans</italic> biofilm with DNase I (5&#x2009;min) before PDZ-aPDT reduced the counting of viable colonies (CFU) and the quantity of eDNA in the ECM (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>). This treatment strategy applied to fluconazole-resistant <italic>C. albicans</italic> biofilm decreased CFU (~1.62 log<sub>10</sub>), water-soluble polysaccharides (36.3%), and eDNA (72.3%) (<xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). Hence, the effect of photodynamic treatment was potentiated because DNase I disturbed the ECM and allowed the diffusion of PDZ and light through the ECM of fluconazole-susceptible and -resistant <italic>C. albicans</italic> biofilm, increasing treatment efficacy (<xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). Hence, the present study evaluated whether the application of DNase could potentiate the action of PDZ-aPDT treatment in mice infected with fluconazole-susceptible and -resistant <italic>C. albicans</italic>, focusing on fungal viable population recovery and resolution of candidiasis lesions on the mice&#x2019;s tongues.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Photosensitizer, DNase enzime and LED parameters</title>
<p>Photodithazine<sup>&#x00AE;</sup> (PDZ) is a chlorin e6 derivative (VETAGRAND, Co, Moscow, Russia), which has an absorption peak of 660&#x2009;nm. The PDZ was prepared on the day of use from the stock solution (5,000&#x2009;mg/L) at a concentration of 200&#x2009;mg/L in natrosol gel (Farm&#x00E1;cia Santa Paula, Araraquara, SP, Brazil) and was kept protected from light (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). The bovine pancreas DNase I enzyme stock solution (AMPD1, Sigma-Aldrich, St. Louis, MO, USA) was prepared on the day of use in 0.1&#x2009;M sodium acetate buffer (pH 5.5) at the concentration of 20&#x2009;units/mL (<xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>).</p>
<p>The red LED light device (LXHLPR09, Luxeon<sup>&#x00AE;</sup> III Emitter, Lumileds Lighting, San Jose, California, USA) was used with an absorption band of 660&#x2009;nm, and the light intensity at the end of the device (5&#x2009;mm in diameter) was 44.6&#x2009;mW/cm<sup>2</sup>. Thus, a light dose of 50J/cm<sup>2</sup> (19&#x2009;min) was applied to the tongues of animals infected with <italic>C. albicans</italic>.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Experimental oral candidiasis and treatments performed</title>
<p>The present study was approved by the Animal Ethics Committee of the School of Dentistry of Araraquara, UNESP (Case number: 09/2020). A total of 180 female mice of the Swiss strain (&#x2245;&#x2009;5&#x2009;weeks old) were used from the vivarium of the School of Dentistry of Araraquara, UNESP. The animals were allocated in cages, with five animals per cage according to the study groups, and kept in a room with a controlled temperature (23&#x2009;&#x00B1;&#x2009;2&#x00B0;C) with standard chow and water <italic>ad libitum</italic> (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>).</p>
<p>Strains of <italic>C. albicans</italic> ATCC (American Type Culture Collection, Rockville, USA), susceptible to fluconazole (ATCC 90028; CaS) and resistant to fluconazole (ATCC 96901; CaR) were defrosted, reactivated on Agar Sabouraud Dextrose (SDA) medium (37&#x00B0;C, 48&#x2009;h). Next, colonies were transferred and cultivated in RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA) buffered to a pH of 7.0 with 3-(N-Morpholino) propanesulfonic acid 4-Morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich, St. Louis, MO, USA) at 37&#x00B0;C for 16&#x2009;h. Then, the cells were washed twice with sterile phosphate buffered saline (PBS) (50&#x2009;mM), resuspended with 3&#x2009;mL of RPMI 1640, and the cell suspension was standardized spectrophotometrically with an optical density (OD) of 540&#x2009;nm (1.0&#x2009;nm&#x2009;&#x00B1;&#x2009;0.08, corresponding to 10<sup>7</sup>&#x2009;CFU/mL) (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>).</p>
<p>For the induction of oral candidiasis, the methodology described before (<xref ref-type="bibr" rid="ref37">Takakura et al., 2003</xref>; <xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>) was used with some modifications. Tetracycline (0.83&#x2009;mg/mL) was administered in the water available to the animals during the experimental period. The animals were immunosuppressed with subcutaneous injections of prednisolone at a dose of 100&#x2009;mg/kg of body mass on days 1, 5, 9, and 13. Inoculation with the strains was performed on day 2 of the experiment (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="ref37">Takakura et al., 2003</xref>; <xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). For this procedure, the animals were sedated with 0.1&#x2009;mL of chlorpromazine hydrochloride (2&#x2009;mg/mL), and sterile mini-swabs soaked in the CaS or CaR suspension were scrubbed across the dorsum of the animals&#x2019; tongues for 30&#x2009;s.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Experimental protocol. On the days 1, 5, 9, and 13 the animals were immunosuppressed with subcutaneous injections of prednisolone. On day 2, the animals were inoculated with CaS or CaR. The treatment was performed during 5&#x2009;days (days 7&#x2013;11). On days 11 and 18, the fungal load was recovered from the mice&#x2019;s tongue. The tongue removal and euthanasia were performed on days 12 and 18. During the experimental period (18&#x2009;days), tetracycline hydrochloride was administered in the water system.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g001.tif"/>
</fig>
<p>On day 7, the presence of white patches or pseudomembranous lesions was verified, and the treatments were performed. The animals were anesthetized with an intraperitoneal injection of ketamine [100&#x2009;mg/kg body weight (National Pharmaceutical Chemistry Union S/A, Embu, SP, Brazil)] and xylazine [10&#x2009;mg/kg body weight (Veterinary JA Ltda., Sponsor Paulista, SP, Brazil)]. Then, the animals were placed in a supine position on the work table, the tongues were gently taken out of the oral cavity, and 50&#x2009;&#x03BC;L of PDZ diluted in natrosol gel (200&#x2009;mg/L) was applied with a pipette (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). The mice stayed in the dark for 20&#x2009;min for a pre-incubation time. Then, each dorsum of the tongue was illuminated with LED for 19&#x2009;min (50&#x2009;J/cm<sup>2</sup>) (P&#x2009;+&#x2009;L+ group). The effect of the isolated application of PDZ (P&#x2009;+&#x2009;L-) and the LED (P-L+ group) was also evaluated. For DNase treatment, the tongue of the mice received 50&#x2009;&#x03BC;L of DNase (20&#x2009;units/mL) for 5&#x2009;min. One group received the combined treatment with the enzyme and PDZ-aPDT (DNase+P&#x2009;+&#x2009;L+ group). After the treatments, neither DNase nor PDZ was removed from the mice&#x2019; tongue. The untreated control group (P-L- group) received no PDZ, light, or DNase. In addition, two additional negative infection control groups (NIC groups) with healthy animals were evaluated. In one of them, mice were immunosuppressed on days 1, 5, 9, and 13 (NIC+ group); in the other group, animals did not receive immunosuppression (NIC- group). Seven animals were evaluated for each experimental condition, except the group NIC+ (<italic>n</italic>&#x2009;=&#x2009;3) and NIC- (<italic>n</italic>&#x2009;=&#x2009;3). The therapies were performed once a day for five consecutive days (from day seven until day 11).</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Fungal viable population</title>
<p>After five consecutive days of treatment (day 11) and 7&#x2009;days after the end of the treatment (day 18), <italic>C. albicans</italic> cells were recovered from the tongue of mice. For this procedure, the mini-swabs were swabbed on the dorsum of each tongue for 1&#x2009;min. Then, they were transferred to tubes with 1&#x2009;mL of saline solution and vortexed for 1&#x2009;min to detach <italic>C. albicans</italic> cells. Then, serial dilutions were made (10<sup>&#x2212;1</sup> a 10<sup>&#x2212;3</sup>) and plated in duplicate in SDA culture medium containing 5&#x2009;&#x03BC;g/mL of chloramphenicol. After 48&#x2009;h of incubation at 37&#x00B0;C, the viable colonies were counted, and the values of CFU/mL were determined.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Macroscopic analysis of tongue&#x2019;s lesions</title>
<p>The white patches or pseudomembranous lesions in the tongues of mice were photographed before the beginning of the treatments, 24&#x2009;h (day 12), and 7&#x2009;days (day 18) after the last application. All photographs were standardized and obtained with the same digital camera (Sony Cyber-Shot DSCF717; Sony Corporation, Tokyo, Japan), by the same operator and under the same conditions (place, light, angle, and position of the animals), thus aiming to facilitate the reproducibility. The extension area of the lesion on the tongue in each photograph was evaluated using the ImageJ.exe program.<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> The percentage of the extension area of each lesion over the total area of the tongue was calculated using this software (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>).</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>Histopathological analyses and animal sacrifice</title>
<p>Initially, mice were anesthetized with an intraperitoneal injection of ketamine and xylazine. Then, animals&#x2019; tongues were surgically removed and destinated for histopathological and fluorescence microscopic analyses. After the tongue excision, mice were euthanized by intramuscular injection of a lethal dose of ketamine (0.2&#x2009;mL) and xylazine (0.4&#x2009;mL) 24&#x2009;h (day 12) and 7&#x2009;days (day 18) after the last application of treatment (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>).</p>
<p>The tongues were placed in plastic cassettes for the histopathological and fluorescence microscopic analyses. These cassettes were immersed in 10% paraformaldehyde (pH 7.2) (441.244, Sigma-Aldrich, St Louis, MO, USA). Then, the histological fixation process was made, and the blocks were fixed on wooden supports and placed in a rotating microtome. Sixteen serial histological sections of each block were obtained. These cuts were placed on glass slides and stained with hematoxylin&#x2013;eosin (HE) stain to evaluate the histological events that occurred in each of the groups through light microscopy [Zeiss microscope LSM 700 (Carl Zeiss, Heidelberg, Germany)] at 100 and 200X magnification. A pathologist performed the histological analysis, and the following aspects were evaluated: the presence/absence of yeast and inflammatory infiltrate, epithelial tissue integrity, and adjacent connective tissue response. The material was classified into scores: 0&#x2014;the absence of inflammation; 1&#x2014;the presence of inflammatory infiltrate; 2&#x2014;moderate inflammation; 3: severe inflammation; and 4: abscess formation (ISO 7405:1997). The evaluation was performed by a single examiner blinded to each experimental group at each evaluated time after treatment.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Microscopy analysis of fluorescence to determine fungal colonization on tongues</title>
<p>Initially, the samples were deparaffinated and hydrated in water. The antigenic retrieval was performed by heat. The sections were then immersed in 10&#x2009;mM buffered sodium citrate, pH 6.0, and placed in the microwave twice for 5&#x2009;min each (<xref ref-type="bibr" rid="ref14">El-Habashi et al., 1995</xref>). Next, the slides were dried, and the sections were circled with a hydrophobic barrier pen (Sigma Advanced PAP Pen-Z377821) and 20&#x2009;&#x03BC;L of the primary antibody (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan (400&#x2013;4) (<xref ref-type="table" rid="tab1">Table 1</xref>) diluted in 2% bovine serum albumin (BSA) and 0.1% Triton X100 (1:20 dilution) was pipetted on each section (<xref ref-type="bibr" rid="ref23">Lobo et al., 2019</xref>). The slides were incubated overnight (4&#x00B0;C). After incubation, sections were carefully washed with 0.89% NaCl solution, and a blocking solution (3% BSA) was added, followed by incubation for 15&#x2009;min (room temperature). Then, the sections were washed again with 0.89% NaCl solution, and the secondary antibody (20&#x2009;&#x03BC;L) labeled with Alexa Fluor&#x00AE; 594&#x2009;nm (1:500 dilution in 2% BSA) was added (<xref ref-type="table" rid="tab1">Table 1</xref>), followed by incubation for 2&#x2009;h (4&#x00B0;C). After the secondary antibody incubation time, the sections were washed with 0.89% NaCl and incubated with 20&#x2009;&#x03BC;L of concavalin-A lectin conjugated with Alexa Fluor<sup>&#x00AE;</sup> 488&#x2009;nm (200&#x2009;&#x03BC;g/mL) (<xref ref-type="table" rid="tab1">Table 1</xref>) and Hoescht (6&#x2009;&#x03BC;g/mL) (<xref ref-type="table" rid="tab1">Table 1</xref>) for 30&#x2009;min. Next, samples were washed with 0.89% NaCl. The mounting media [Fluoromount <sup>&#x2122;</sup> Aqueous Mounting Medium (F4680, Sigma-Aldrich, St Louis, MO, USA)] was added, and the slides were ready for image acquisition. Images were acquired using the Leica DM2500 LED microscope (Leica Microsystems, Wetzlar, Germany).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Probes and stains used in the fluorescence microscopic analysis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Labeling target</th>
<th align="left" valign="top">Labeling (stain or probe) (excitation/emission nm)</th>
<th align="left" valign="top">Brand</th>
<th align="left" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">
<italic>C. albicans</italic>
</td>
<td align="left" valign="top">ConcanavalinA (ConA) lectin conjugated with tetramethylrhodamine (488/520&#x2009;nm)</td>
<td align="left" valign="top">Molecular Probes (Cat. No. C860)</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref23">Lobo et al. (2019)</xref> and <xref ref-type="bibr" rid="ref15">Falsetta et al. (2014)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Nucleic acids</td>
<td align="left" valign="top">HOESCHT 33342</td>
<td align="left" valign="top">ABCAM Staining Staining Dye Solution (Cat. No. ab228551)</td>
<td align="left" valign="top">
<xref ref-type="bibr" rid="ref10">Chazotte (2011)</xref>
</td>
</tr>
<tr>
<td align="left" valign="top">Polysaccharides produced by <italic>C. albicans</italic></td>
<td align="left" valign="top">Primary monoclonal antibody to (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan</td>
<td align="left" valign="top">Biosupplies (Cat. No. 400-4)</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref23">Lobo et al. (2019)</xref> and <xref ref-type="bibr" rid="ref40">Wartenberg et al. (2014)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Secondary antibody</td>
<td align="left" valign="top">Goat Anti-Mouse IgG H&#x0026;L (Alexa Fluor<sup>&#x00AE;</sup> 594) (561/620&#x2009;nm)</td>
<td align="left" valign="top">Abcam (Cat. No. ab175660)</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref23">Lobo et al. (2019)</xref> and <xref ref-type="bibr" rid="ref40">Wartenberg et al. (2014)</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec9">
<label>2.7</label>
<title>Statistical analysis</title>
<p>Analyses were performed using the IBM SPSS Statistics for Windows Version 27; IBM Corp., Armonk, NY, USA. Data from each strain was evaluated separately. The normality and homoscedasticity of the data from CFU converted in base-10 logarithms for each strain were assessed using the Shapiro&#x2013;Wilk and Levene&#x2019;s tests, respectively. The data were normal and heteroscedastic, so they were analyzed by a two-way ANOVA test, considering two treatment evaluation periods (immediate and 7&#x2009;days after). Games-Howell post-hoc analysis was performed for multiple comparisons (<italic>&#x03B1;</italic>&#x2009;=&#x2009;5%). The percentage values of tongue&#x2019;s lesions assumed normality and were homoscedastic for the data evaluated in both periods (24&#x2009;h and 7&#x2009;days after the treatments) for CaS and CaR. Thus, they were analyzed by one-way ANOVA, followed by Tukey&#x2019;s post-hoc (<italic>&#x03B1;</italic>&#x2009;=&#x2009;5%). Descriptive analyses were performed for the images obtained for the histopathological and fluorescence microscopy evaluations.</p>
</sec>
</sec>
<sec sec-type="results" id="sec10">
<label>3</label>
<title>Results</title>
<sec id="sec11">
<label>3.1</label>
<title>Fungal viable population from mice inoculated with CaS and CaR</title>
<p>The results of viability from CaS immediately after the treatments demonstrated that the animals treated with DNase followed by PDZ-aPDT (DNase+P&#x2009;+&#x2009;L+ group) showed the highest log<sub>10</sub> reduction value (CFU/mL), compared to the negative control group (P-L-) equivalent to 4.26 log<sub>10</sub> (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and different from the other groups and the control (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The P&#x2009;+&#x2009;L+ group (PDZ-aPDT) showed a reduction of approximately 2.50 log<sub>10</sub> compared to the control (P-L- group) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The other groups showed statistically similar values with the control (P-L-) (<italic>p</italic>&#x2009;&#x2265;&#x2009;0.05) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Mean values +/&#x2212; standard deviation of log<sub>10</sub> (CFU/mL) for different experimental groups and periods evaluated (immediately and 7 days after treatments) for animals inoculated with CaS. Different number of asterisks denotes statistical difference between the groups.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g002.tif"/>
</fig>
<p>The results of CaR showed that DNase+P&#x2009;+&#x2009;L+ group immediately after the treatments was statistically different from the other groups and exhibited the highest log<sub>10</sub> reduction value (CFU/mL), compared to the P-L-group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001), equivalent to 2.89 log<sub>10</sub> (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The group treated only with PDZ-aPDT (P&#x2009;+&#x2009;L+ group) showed a reduction of 0.34 log<sub>10</sub> compared to the P-L- group. The P&#x2009;+&#x2009;L-, P-L+, P&#x2009;+&#x2009;L+, DNase and P-L-groups presented statistically similar effects (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Mean values +/&#x2212; standard deviation of log<sub>10</sub> (CFU/mL) for different experimental groups and periods evaluated (immediately and 7 days after treatments) for animals inoculated with CaR. Different number of asterisks denotes statistical difference between the groups.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g003.tif"/>
</fig>
<p>The results of 7&#x2009;days after the end of the treatments demonstrated that the DNase+P&#x2009;+&#x2009;L+ group exhibited the greatest reduction in the viable colonies of CaS when compared to the negative control group (P-L-) (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001); this reduction was approximately 1.97 log<sub>10</sub> (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The P&#x2009;+&#x2009;L+ group was similar to DNase+P&#x2009;+&#x2009;L+ group and showed a statistically different value from the other groups, with a reduction of 1.18 log<sub>10</sub> compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The other experimental groups (P&#x2009;+&#x2009;L-, P-L+, DNase) showed statistically similar effects among themselves and with the negative control (P-L-) (<italic>p</italic>&#x2009;&#x2265;&#x2009;0.05) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
<p>For CaR after 7&#x2009;days of the end of the treatments, the DNase+P&#x2009;+&#x2009;L+ group showed the greatest reduction in viable colonies when compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001), with a reduction of approximately 1.27 log<sub>10</sub> (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The P&#x2009;+&#x2009;L+ group showed a reduction of 0.22 log<sub>10</sub> compared to the P-L- group. The other experimental groups (P&#x2009;+&#x2009;L-, P-L+, P&#x2009;+&#x2009;L+, and DNase) showed statistically similar values among themselves and the P-L- group (<italic>p</italic>&#x2009;&#x2265;&#x2009;0.05) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
</sec>
<sec id="sec12">
<label>3.2</label>
<title>Clinical evaluation from mice inoculated with CaS and CaR</title>
<p>The results after 24&#x2009;h of treatment (<xref ref-type="fig" rid="fig4">Figure 4</xref>) for mice inoculated with the CaS showed that the DNase+P&#x2009;+&#x2009;L+ and P&#x2009;+&#x2009;L+ groups significantly reduced oral lesions by 98.92 and 97.71%, respectively, when compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The results for 7&#x2009;days after the treatments showed a reduction in oral lesions of 83.31% for DNase+P&#x2009;+&#x2009;L+ group, compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The DNase+P&#x2009;+&#x2009;L+ group was statistically different from P&#x2009;+&#x2009;L+ group that reduced the oral lesions by around 63.81% compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The other groups evaluated immediately and after 7&#x2009;days (<xref ref-type="fig" rid="fig4">Figure 4</xref>) showed a statistically similar effect to the P-L- control (<italic>p</italic>&#x2009;&#x2265;&#x2009;0.05). The images presented in <xref ref-type="fig" rid="fig5">Figure 5</xref> illustrate the presence of white patches or pseudomembranous plaques on the dorsum of the animals&#x2019; tongues inoculated with CaS for each group 24&#x2009;h and 7&#x2009;days after the treatments.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Mean values +/&#x2212; standard deviation of the lesion size (with the size of the patches) in percentages (%) on the tongue&#x2019;s dorsum of the mice inoculated with CaS evaluated 24 h (black circle) and 7 days (blue circle) after the end of the treatments. &#x002A; denotes statistical difference. Different number of asterisks denotes statistical difference between the groups.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g004.tif"/>
</fig>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Representative images of the white or pseudomembranous patches of mice&#x2019; tongues inoculated with CaS for the groups P-L-, P&#x2009;+&#x2009;L-, P-L+, and DNase 24&#x2009;h and 7&#x2009;days after the end of treatment. Also, representative images of the remission of tongue lesions were observed in the mice submitted to the P&#x2009;+&#x2009;L+ 24&#x2009;h and DNase+P&#x2009;+&#x2009;L+ 24&#x2009;h and 7&#x2009;days after the treatments.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g005.tif"/>
</fig>
<p>The results obtained for CaR (<xref ref-type="fig" rid="fig6">Figure 6</xref>) demonstrated that the DNase+P&#x2009;+&#x2009;L+ and P&#x2009;+&#x2009;L+ groups immediately after the treatments exhibited reductions of oral lesions by 96.07 and 50.41%, respectively, when compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). Immediately after the treatments, the other groups showed a statistically similar effect to the P-L- group (p&#x2009;&#x2265;&#x2009;0.05). In addition, 7&#x2009;days after the treatments, the DNase+P&#x2009;+&#x2009;L+ group showed a significant reduction in oral lesions by 75.24% when compared to the P-L- group (<italic>p</italic>&#x2009;&#x2264;&#x2009;0.0001). The other groups showed statistically similar values to the P-L- control (<italic>p</italic>&#x2009;&#x2265;&#x2009;0.05) (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Mean values +/&#x2212; standard deviation of the lesion size (with the size of the patches) in percentages (%) on the tongue&#x2019;s dorsum of the mice inoculated with CaR evaluated 24 h (black circle) and 7 days (blue circle) after the end of the treatment. &#x002A; denotes statistical difference. Different number of asterisks denotes statistical difference between the groups.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g006.tif"/>
</fig>
<p>The images in <xref ref-type="fig" rid="fig7">Figure 7</xref> illustrate the presence of white patches or pseudomembranous plaques on the dorsum of the tongues 24&#x2009;h and 7&#x2009;days after the treatments performed on animals inoculated with CaR (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>Representative images of the white or pseudomembranous patches of mice&#x2019; tongues inoculated with CaR for the groups P-L-, P&#x2009;+&#x2009;L-, P-L+, P&#x2009;+&#x2009;L+, and DNase 24&#x2009;h and 7&#x2009;days after the end of treatment. Also, representative images of the remission of tongue lesions in the mice submitted to the DNase+P&#x2009;+&#x2009;L+ treatment are observed 24&#x2009;h and 7&#x2009;days after the treatment.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g007.tif"/>
</fig>
</sec>
<sec id="sec13">
<label>3.3</label>
<title>Histopathological evaluation</title>
<p>The histopathological evaluation demonstrated that the sections from tongues contaminated with CaS exhibited mild inflammatory infiltrates for groups DNase+P&#x2009;+&#x2009;L+ and P&#x2009;+&#x2009;L+ 24&#x2009;h after the treatment (<xref ref-type="fig" rid="fig8">Figure 8</xref>). These groups presented histopathological characteristics similar to those observed in the NIC- and NIC+ groups. The stratified epithelium exhibited normal and healthy features, with lingual papillae covered by a fine keratin layer. The other groups (P-L-, P-L+, P&#x2009;+&#x2009;L- and DNase) presented similar histopathological characteristics with moderate inflammatory infiltration and the presence of numerous hyphae/pseudohyphae on the keratin layer and some hyphae/pseudohyphae invading the epithelial tissue of the tongues (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Regarding the histological sections evaluated at 7&#x2009;days after the treatment for CaS, the morphological characteristics remained relatively unchanged, with the exception of the P-L-, P&#x2009;+&#x2009;L-, P-L+, and DNase groups, which showed moderately degraded muscle tissue (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption>
<p>Representative images of the histological sections of tongues from mice inoculated with CaS and recovered 24&#x2009;h and 7&#x2009;days after the end of treatments. Muscle tissue was stained with hematoxylin&#x2013;eosin (HE) (40X). Black arrow &#x2013; keratin layer contaminated with hyphae and pseudohyphae; green arrow &#x2013; lamina propria and yellow arrow &#x2013; dilated blood vessels in response to the local inflammatory reaction.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g008.tif"/>
</fig>
<p>For the animals inoculated with CaR (<xref ref-type="fig" rid="fig9">Figure 9</xref>), the group treated with DNase+P&#x2009;+&#x2009;L+ presented histopathological characteristics similar to those observed in the NIC- and NIC+ groups (<xref ref-type="fig" rid="fig8">Figure 8</xref>) after 24&#x2009;h of the treatments. The stratified epithelium exhibited normal and healthy features, with lingual papillae covered by a fine keratin layer (<xref ref-type="fig" rid="fig9">Figure 9</xref>). The group treated with P&#x2009;+&#x2009;L+ showed a greater number of hyphae and pseudohyphae within the keratin epithelial layer. The animals in the P-L-, P&#x2009;+&#x2009;L-, P-L+, and DNase groups presented extensive amounts of <italic>C. albicans</italic> covering the epithelial tissue, and there was a loss of the papillae (<xref ref-type="fig" rid="fig9">Figure 9</xref>). This epithelium showed intense inflammation with the existence of mononuclear cells inside the dilated blood vessels caused by the inflammation. The underlying connective tissue was formed by muscle fibers with normal characteristics.</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption>
<p>Representative images of the histological sections of tongues from mice inoculated with CaR and recovered 24&#x2009;h and 7&#x2009;days after the end of treatments. Muscle tissue was stained with hematoxylin&#x2013;eosin (HE) (40X). Black arrow &#x2013; keratin layer contaminated with hyphae and pseudohyphae; green arrow &#x2013; lamina propria and yellow arrow &#x2013; dilated blood vessels in response to local inflammatory reaction.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g009.tif"/>
</fig>
<p>The histological findings 7&#x2009;days after treatments (<xref ref-type="fig" rid="fig9">Figure 9</xref>) for the P-L-, P&#x2009;+&#x2009;L-, P-L+, and DNase groups contaminated with CaR were similar to those observed 24&#x2009;h after treatments associated with damage in the muscular tissue. In the P&#x2009;+&#x2009;L+ and DNase+P&#x2009;+&#x2009;L+ groups, many hyphae and pseudohyphae were observed in the epithelium keratin layer, but the epithelial tissue remained with normal characteristics (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p>
</sec>
<sec id="sec14">
<label>3.4</label>
<title>Microscopy fluorescence evaluation</title>
<p>The representative images from animals for P-L- group inoculated with CaS and CaR 24&#x2009;h after the treatment (<xref ref-type="fig" rid="fig10">Figures 10</xref>, <xref ref-type="fig" rid="fig11">11</xref>, respectively) showed a thick layer of biofilm (green) surrounded by polysaccharides (1&#x2013;4 &#x03B2;-mannan and galacto) (red) produced by <italic>C. albicans</italic>. The images of DNase+P&#x2009;+&#x2009;L+ group presented similarity with NIC group once the polysaccharides (red) and fungal cells (green) were not labeled. The P&#x2009;+&#x2009;L+ group showed a small amount of biofilm (green) and polysaccharides (red) (<xref ref-type="fig" rid="fig10">Figures 10</xref>, <xref ref-type="fig" rid="fig11">11</xref>).</p>
<fig position="float" id="fig10">
<label>Figure 10</label>
<caption>
<p>Representative fluorescence microscopy images of histological tongues sections recovered 24&#x2009;h after treatments from the mice inoculated with CaS, labeled with Hoestch (first left column), concanavalin A conjugated with Alexa 488&#x2009;nm (second column), and with primary antibody (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan (400&#x2013;4) paired with secondary antibody conjugated with Alexa Fluoride 594&#x2009;nm (third column). The tongue tissue cells (cell nucleus) were represented by the color blue. Fungal cells and matrix polysaccharides of <italic>C. albicans</italic> were represented by the colors green, and red, respectively. In the last column are the merged images.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g010.tif"/>
</fig>
<fig position="float" id="fig11">
<label>Figure 11</label>
<caption>
<p>Representative fluorescence microscopy images of histological tongues sections recovery 24&#x2009;h after the treatments from the mice inoculated with CaR, labeled with Hoestch (first left column), concanavalin A conjugated with Alexa 488&#x2009;nm (second column), and with primary antibody (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan (400&#x2013;4) paired with secondary antibody conjugated with Alexa Fluoride 594&#x2009;nm (third column). The tongue tissue cells (cell nucleus) were represented by the color blue. Fungal cells and matrix polysaccharides of <italic>C. albicans</italic> were represented by the colors green and red, respectively. In the last column are the merged images.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g011.tif"/>
</fig>
<p>After 7&#x2009;days of the treatment for CaS and CaR (<xref ref-type="fig" rid="fig12">Figures 12</xref>, <xref ref-type="fig" rid="fig13">13</xref>), the P-L- group was labeled with polysaccharides produced by <italic>C. albicans</italic> (red), with higher intensity of label in fungal cells (green) (<xref ref-type="fig" rid="fig12">Figures 12</xref>, <xref ref-type="fig" rid="fig13">13</xref>). The DNase+P&#x2009;+&#x2009;L+ group of animals contaminated with CaS presented a small layer of <italic>C. albicans</italic> biofilm and polysaccharides (red color) (<xref ref-type="fig" rid="fig12">Figure 12</xref>). The P&#x2009;+&#x2009;L+ group demonstrated a slight presence of fungal biofilm (green) and polysaccharides (red color) (<xref ref-type="fig" rid="fig12">Figure 12</xref>). For CaR, the group DNase+P&#x2009;+&#x2009;L+ presented less biofilm and polysaccharides than the group treated only with PDZ-aPDT (P&#x2009;+&#x2009;L+ group) once there was a thick layer of CaR biofilm (green) surrounded by polysaccharides (red) (<xref ref-type="fig" rid="fig13">Figure 13</xref>).</p>
<fig position="float" id="fig12">
<label>Figure 12</label>
<caption>
<p>Representative fluorescence microscopy images of histological tongues sections recovered 7&#x2009;days after the end of treatments from the mice inoculated with CaS, labeled with Hoestch (first left column), concanavalin A conjugated with Alexa 488&#x2009;nm (second column), and with primary antibody (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan (400&#x2013;4) paired with secondary antibody conjugated with Alexa Fluoride 594&#x2009;nm (third column). The tongue tissue cells (cell nucleus) were represented by the color blue. Fungal cells and matrix polysaccharides of <italic>C. albicans</italic> were represented by the colors green and red, respectively. In the last column are the merged images.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g012.tif"/>
</fig>
<fig position="float" id="fig13">
<label>Figure 13</label>
<caption>
<p>Representative fluorescence microscopy images of histological tongues sections recovery 7&#x2009;days after the end of treatments from the mice inoculated with CaR, labeled with Hoestch (first left column), concanavalin A conjugated with Alexa 488&#x2009;nm (second column), and with primary antibody (1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan and galacto-(1&#x2009;&#x2192;&#x2009;4)-&#x03B2;-mannan (400&#x2013;4) paired with secondary antibody conjugated with Alexa Fluoride 594&#x2009;nm (third column). The tongue tissue cells (cell nucleus) were represented by the color blue. Fungal cells and matrix polysaccharides of <italic>C. albicans</italic> were represented by green and red, respectively. In the last column are the merged images.</p>
</caption>
<graphic xlink:href="fmicb-14-1274201-g013.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec15">
<label>4</label>
<title>Discussion</title>
<p><italic>In vitro</italic> studies report the improved efficacy of PDZ-aPDT combined with DNase against <italic>C. albicans</italic> biofilms (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>; <xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). Enzymes decrease the integrity of the ECM by hydrolyzing proteins, polysaccharides, and nucleic acids. DNase I reduces biofilm stability, increasing the susceptibility of the biofilm to the action of antifungals and aPDT (<xref ref-type="bibr" rid="ref22">Liao, 1974</xref>; <xref ref-type="bibr" rid="ref25">Martins et al., 2012</xref>; <xref ref-type="bibr" rid="ref38">Tetz and Tetz, 2016</xref>; <xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>; <xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). The current study investigated whether applying DNase I enzyme could potentiate PDZ-aPDT outcomes in mice infected by susceptible- and fluconazole-resistant <italic>C. albicans</italic>. Here, DNase I (20&#x2009;units/mL) combined with PDZ-aPDT promoted antifungal effects against CaR in the oral lesions of mice with experimental oral candidiasis, and macroscopic analysis showed that 24&#x2009;h after completion of treatment, the animals presented 96.7% remission of lesions. To our knowledge, no previous published study has investigated <italic>in vivo</italic> the efficacy of DNase I associated with aPDT in treating induced oral candidiasis in mice.</p>
<p>The results from mice inoculated with CaR showed that DNase I prior PDZ-aPDT promoted a reduction in viable colony counts by around 2.89 and 1.27 log<sub>10</sub>, respectively, immediately and 7&#x2009;days after the treatments. In addition, the macroscopic oral lesions were reduced by around 96.07 and 75.24% 24&#x2009;h and 7&#x2009;days after the treatment, respectively. These results observed here corroborate with a previous study (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>), that evaluated the combination of PDZ (200&#x2009;mg/L) mediated aPDT associated with nystatin in the treatment of mice infected with fluconazole-resistant <italic>C. albicans</italic> (ATCC 96901). Using the same methodology for induction of infection in mice, the combination of treatments reduced ~2.60 log<sub>10</sub> the fungal viability and&#x2009;~&#x2009;95% the macroscopic oral lesions 24&#x2009;h after the treatment (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). The results obtained after 7&#x2009;days of the end treatment showed that nystatin combined with PDZ-aPDT promoted a reduction of ~1 log<sub>10</sub> in fungal viability and macroscopic reduction in oral lesions by around ~50% (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). Here, DNase yielded an outcome more favorable than nystatin in decreasing fungal viability and reducing the rate of lesion recurrence. Using alternative sources can lead to access to novel therapeutic agents with fewer side effects without the risk of antifungal resistance (<xref ref-type="bibr" rid="ref35">Sandai et al., 2016</xref>; <xref ref-type="bibr" rid="ref39">Torabi et al., 2022</xref>). DNase may be an adjuvant for biofilm treatments since it degrades eDNA in the extracellular matrix of biofilms (<xref ref-type="bibr" rid="ref33">Rajendran et al., 2014</xref>; <xref ref-type="bibr" rid="ref17">Hamblin and Abrahamse, 2019</xref>). Therefore, we suggest that DNase enabled PDZ diffusion in the extracellular matrix of biofilms, potentiating the effects of PDZ-aPDT and promoting the inactivation of biofilms <italic>in vivo</italic>.</p>
<p>The enzyme associated with PDZ-aPDT reduced the fungal viability of CaS by around 4.26 and 1.97 log<sub>10</sub>, respectively, immediately and 7&#x2009;days after the treatments. In addition, there was a remission in the oral lesions, around 98.92 and 83.31%, respectively, after 24&#x2009;h and 7&#x2009;days. <italic>In vivo</italic> investigation (<xref ref-type="bibr" rid="ref9">Carmello et al., 2015</xref>) demonstrated that five applications of PDZ-aPDT or antifungal nystatin promoted reductions in the cell viability of <italic>C. albicans</italic> (ATCC 90028) of 3 and 3.22 logs<sub>10</sub>, respectively 24&#x2009;h after the treatment (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>). After 7&#x2009;days of treatment, a reduction of ~2 log<sub>10</sub> for PDZ-aPDT and nystatin groups was observed (<xref ref-type="bibr" rid="ref8">Carmello et al., 2016</xref>). Compared to antifungal, the lack of development of antimicrobial resistance increases further studies using aPDT (<xref ref-type="bibr" rid="ref17">Hamblin and Abrahamse, 2019</xref>). Thus, our findings revealed that DNase improves aPDT outcomes, being a promising alternative for fungal inactivation, including resistant microorganisms.</p>
<p>DNase I (5&#x2009;min) combined with PDZ-aPDT decreased the fungal viability in ~2.16 log<sub>10</sub> and the levels of eDNA in the ECM of biofilms formed by fluconazole-susceptible <italic>C. albicans</italic> (ATCC 90028) (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>). When fluconazole-resistant <italic>C. albicans</italic> biofilms were treated with DNase prior to the PDZ-aPDT, there was a decrease of ~1.92 log<sub>10</sub> in the fungal viability, water-soluble polysaccharides (36.3%), and eDNA (72.3%) (<xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>). Here, the fluorescence microscopy images of histological tongue sections 24&#x2009;h after treatment demonstrated that DNase I before PDZ-aPDT promoted a reduction in fungal polysaccharides, similar to healthy animals (NIC). After 7&#x2009;days of the treatment, the presence of polysaccharides was observed only in mice infected by fluconazole-resistant <italic>C. albicans</italic>. Still, the fungal viable count was smaller than that in the PDZ-aPDT group. Thus, DNase treatment reduced the fungal polysaccharides <italic>in vitro</italic> (<xref ref-type="bibr" rid="ref31">Panariello et al., 2019</xref>; <xref ref-type="bibr" rid="ref1">Abreu-Pereira et al., 2022</xref>) and in the animal model here. Among the components present in the ECM, eDNA, associated with &#x03B2;-glucans and &#x03B2;-mannans, contributes to the organizational integrity of biofilms and antifungal tolerance of <italic>C. albicans</italic> (<xref ref-type="bibr" rid="ref25">Martins et al., 2012</xref>; <xref ref-type="bibr" rid="ref33">Rajendran et al., 2014</xref>; <xref ref-type="bibr" rid="ref27">Mitchell et al., 2016</xref>). Some reports found an association between eDNA levels and increased microbial resistance to antibiotics (<xref ref-type="bibr" rid="ref34">Rice et al., 2007</xref>; <xref ref-type="bibr" rid="ref11">da Silva et al., 2008</xref>). Therefore, disrupting the ECM and reducing eDNA levels of <italic>C. albicans</italic> biofilms are essential to optimize antifungal therapies.</p>
<p>The histological sections of the tongues recovered after the treatment with DNase before PDZ-aPDT for both strains (CaS and CaR) demonstrated histological characteristics similar to those of the NIC group (healthy animals). The tissues presented a reduced amount of hyphae/pseudohyphae/blastopore on the keratin layer, minor inflammation in the subjacent connective tissue, and intact muscle tissue. In a previous study, mice treated with 5 applications of nystatin associated with PDZ-aPDT presented normal histological characteristics, which are outcomes very similar to those observed in the present study (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). In addition, the inoculation of mice with fluconazole-resistant <italic>C. albicans</italic> promoted an intense inflammatory response in the subjacent connective tissue (<xref ref-type="bibr" rid="ref4">Alves et al., 2018</xref>; <xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>) and 5 applications of PDZ-aPDT decreased an inflammatory reaction from intense to mild (<xref ref-type="bibr" rid="ref18">Hidalgo et al., 2019</xref>). Here, the control groups (P-L-, P&#x2009;+&#x2009;L-, P-L+, and DNase) 24&#x2009;h after the treatment presented a large area of hyphae/pseudohyphaes covering the epithelial tissue, which demonstrated acanthosis associated with the papillae destruction.</p>
<p>Moreover, there is an intense inflammation of the epithelium with dilated blood vessels. Seven days after the treatments, the muscle fibers were partially degraded in the superficial region of the tissue in the control groups (P-L-, P&#x2009;+&#x2009;L-, and P-L+ groups). In the sections from animals inoculated with CaR, 7&#x2009;days after the end of treatment, there were hyphae and pseudohyphae on the keratin layer, suggesting recurrence of the oral infection in the DNase+P&#x2009;+&#x2009;L+ group, but its keratin layer was smaller than that observed for P&#x2009;+&#x2009;L+ group. Furthermore, in the PDZ-aPDT group, there was a return in the oral lesions. Our results demonstrated that DNase before PDZ-aPDT reduces the lesion recurrence rate after 7&#x2009;days compared to other treatments for fluconazole-resistant <italic>C. albicans</italic>. Therefore, DNase I affected the biofilm composition and hampered the new formation of <italic>C. albicans</italic> biofilm, probably because the complete epithelial restructuring was promoted in the groups treated with DNase+P&#x2009;+&#x2009;L+.</p>
<p>The overall increased occurrences of pathogens resistant to conventional antifungals and the toxicity of drugs have motivated searches for strategies to inactivate fungal species. In addition, the ECM of <italic>C. albicans</italic> biofilms limits the penetration of antimicrobials, antiseptics, and photosensitizers, influencing the efficacy of aPDT and other fungal therapies. In summary, DNase before PDZ-aPDT promoted expressive outcomes by reducing fungal viability and healing the oral lesions in mice. Therefore, this study further demonstrates that DNase is a promising alternative adjuvant for fungal photoinactivation <italic>in vivo</italic> of antifungal-susceptible and -resistant strains.</p>
</sec>
<sec sec-type="data-availability" id="sec16">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec17">
<title>Ethics statement</title>
<p>The animal studies were approved by Animal Ethics Committee of the School of Dentistry of Araraquara, UNESP (Case number: 09/2020). The studies were conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec18">
<title>Author contributions</title>
<p>CJ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. MK: Conceptualization, Validation, Writing &#x2013; review &#x0026; editing. PB: Methodology, Writing &#x2013; review &#x0026; editing. EM: Writing &#x2013; review &#x0026; editing. TS: Methodology, Writing &#x2013; review &#x0026; editing. TF: Formal analysis, Methodology, Writing &#x2013; review &#x0026; editing. AP: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec19">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was based on the PhD Thesis of the author CJ. This work was supported by the S&#x00E3;o Paulo Research Foundation [FAPESP #2013/07276-1 (RIDC) and #2020/09332-0] and scholarship (FAPESP #2019/27634-6 to CJ and #2021/01191-0 to TF). Additional financial support was provided by the National Council for Scientific and Technological Development (CNPq #304787/2020-5) and PROPG-UNESP (# 69/2023-3032).</p>
</sec>
<sec sec-type="COI-statement" id="sec20">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn id="fn0001">
<p><sup>1</sup><ext-link xlink:href="https://imagej.nih.gov/ij/docs/install/windows.html" ext-link-type="uri">https://imagej.nih.gov/ij/docs/install/windows.html</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abreu-Pereira</surname> <given-names>C. A.</given-names></name> <name><surname>Klein</surname> <given-names>M. I.</given-names></name> <name><surname>Lobo</surname> <given-names>C. I. V.</given-names></name> <name><surname>Gorayb Pereira</surname> <given-names>A. L.</given-names></name> <name><surname>Jord&#x00E3;o</surname> <given-names>C. C.</given-names></name> <name><surname>Pavarina</surname> <given-names>A. C.</given-names></name></person-group> (<year>2022</year>). <article-title>DNase enhances photodynamic therapy against fluconazole-resistant <italic>Candida albicans</italic> biofilms</article-title>. <source>Oral Dis.</source> <volume>29</volume>, <fpage>1855</fpage>&#x2013;<lpage>1867</lpage>. doi: <pub-id pub-id-type="doi">10.1111/odi.14149</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akpan</surname> <given-names>A.</given-names></name> <name><surname>Morgan</surname> <given-names>R.</given-names></name></person-group> (<year>2002</year>). <article-title>Oral candidiasis</article-title>. <source>Postgrad. Med. J.</source> <volume>78</volume>, <fpage>455</fpage>&#x2013;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1136/pmj.78.922.455</pub-id>, PMID: <pub-id pub-id-type="pmid">12185216</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Fattani</surname> <given-names>M. A.</given-names></name> <name><surname>Douglas</surname> <given-names>L. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Biofilm matrix of <italic>Candida albicans</italic> and <italic>Candida tropicalis</italic>: chemical composition and role in drug resistance</article-title>. <source>J. Med. Microbiol.</source> <volume>55</volume>, <fpage>999</fpage>&#x2013;<lpage>1008</lpage>. doi: <pub-id pub-id-type="doi">10.1099/jmm.0.46569-0</pub-id>, PMID: <pub-id pub-id-type="pmid">16849719</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname> <given-names>F.</given-names></name> <name><surname>Carmello</surname> <given-names>J. C.</given-names></name> <name><surname>Mima</surname> <given-names>E. G. O.</given-names></name> <name><surname>Costa</surname> <given-names>C. A. S.</given-names></name> <name><surname>Bagnato</surname> <given-names>V. S.</given-names></name> <name><surname>Pavarina</surname> <given-names>A. C.</given-names></name></person-group> (<year>2018</year>). <article-title>Photodithazine-mediated antimicrobial photodynamic therapy against fluconazole-resistant <italic>Candida albicans in vivo</italic></article-title>. <source>Med. Mycol.</source> <volume>57</volume>, <fpage>609</fpage>&#x2013;<lpage>617</lpage>. doi: <pub-id pub-id-type="doi">10.1093/mmy/myy083</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>G. G.</given-names></name> <name><surname>O'Toole</surname> <given-names>G. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Innate and induced resistance mechanisms of bacterial biofilms</article-title>. <source>Curr. Top. Microbiol. Immunol.</source> <volume>322</volume>, <fpage>85</fpage>&#x2013;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-3-540-75418-3_5</pub-id> PMID: <pub-id pub-id-type="pmid">18453273</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonnett</surname> <given-names>R.</given-names></name> <name><surname>Mart&#x00ED;nez</surname> <given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Photobleaching of sensitisers used in photodynamic therapy</article-title>. <source>Tetrahedron</source> <volume>57</volume>, <fpage>9513</fpage>&#x2013;<lpage>9547</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0040-4020(01)00952-8</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campoy</surname> <given-names>S.</given-names></name> <name><surname>Adrio</surname> <given-names>J. L.</given-names></name></person-group> (<year>2017</year>). <article-title>Antifungals</article-title>. <source>Biochem. Pharmacol.</source> <volume>133</volume>, <fpage>86</fpage>&#x2013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2016.11.019</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carmello</surname> <given-names>J. C.</given-names></name> <name><surname>Alves</surname> <given-names>F.</given-names></name> <name><surname>Basso</surname> <given-names>F. G.</given-names></name> <name><surname>de Souza Costa</surname> <given-names>C. A.</given-names></name> <name><surname>Bagnato</surname> <given-names>V. S.</given-names></name> <name><surname>Mima</surname> <given-names>E. G. O.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Treatment of oral candidiasis using Photodithazine&#x00AE;- mediated photodynamic therapy <italic>in vivo</italic></article-title>. <source>PLoS One</source> <volume>11</volume>:<fpage>e0156947</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0156947</pub-id>, PMID: <pub-id pub-id-type="pmid">27253525</pub-id></citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carmello</surname> <given-names>J. C.</given-names></name> <name><surname>Dovigo</surname> <given-names>L. N.</given-names></name> <name><surname>Mima</surname> <given-names>E. G.</given-names></name> <name><surname>Jorge</surname> <given-names>J. H.</given-names></name> <name><surname>de Souza Costa</surname> <given-names>C. A.</given-names></name> <name><surname>Bagnato</surname> <given-names>V. S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title><italic>In vivo</italic> evaluation of photodynamic inactivation using Photodithazine&#x00AE; against <italic>Candida albicans</italic></article-title>. <source>Photochem. Photobiol. Sci.</source> <volume>14</volume>, <fpage>1319</fpage>&#x2013;<lpage>1328</lpage>. doi: <pub-id pub-id-type="doi">10.1039/c4pp00368c</pub-id>, PMID: <pub-id pub-id-type="pmid">26069900</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chazotte</surname> <given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Labeling nuclear DNA with hoechst 33342</article-title>. <source>Cold Spring Harb. Protoc.</source> <volume>2011</volume> doi: <pub-id pub-id-type="doi">10.1101/pdb.prot5557</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname> <given-names>W. J.</given-names></name> <name><surname>Seneviratne</surname> <given-names>J.</given-names></name> <name><surname>Parahitiyawa</surname> <given-names>N.</given-names></name> <name><surname>Rosa</surname> <given-names>E. A.</given-names></name> <name><surname>Samaranayake</surname> <given-names>L. P.</given-names></name> <name><surname>Del Bel Cury</surname> <given-names>A. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Improvement of XTT assay performance for studies involving <italic>Candida albicans</italic> biofilms</article-title>. <source>Braz. Dent. J.</source> <volume>19</volume>, <fpage>364</fpage>&#x2013;<lpage>369</lpage>. doi: <pub-id pub-id-type="doi">10.1590/S0103-64402008000400014</pub-id>, PMID: <pub-id pub-id-type="pmid">19180329</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname> <given-names>R. F.</given-names></name> <name><surname>McCarron</surname> <given-names>P. A.</given-names></name> <name><surname>Tunney</surname> <given-names>M. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Antifungal photodynamic therapy</article-title>. <source>Microbiol. Res.</source> <volume>163</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micres.2007.08.001</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eggimman</surname> <given-names>P.</given-names></name> <name><surname>Garbino</surname> <given-names>J.</given-names></name> <name><surname>Pittet</surname> <given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Epidemiology of <italic>Candida</italic> species infections in critically ill non-imunossupressed patients</article-title>. <source>Lancet Infect. Dis.</source> <volume>3</volume>, <fpage>685</fpage>&#x2013;<lpage>702</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(03)00801-6</pub-id>, PMID: <pub-id pub-id-type="pmid">14592598</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Habashi</surname> <given-names>A.</given-names></name> <name><surname>El-Morsi</surname> <given-names>B.</given-names></name> <name><surname>Freeman</surname> <given-names>S. M.</given-names></name> <name><surname>El-Didi</surname> <given-names>M.</given-names></name> <name><surname>Aizen</surname> <given-names>J.</given-names></name> <name><surname>Marrogi</surname> <given-names>M. D.</given-names></name></person-group> (<year>1995</year>). <article-title>Tumor oncogenic expression in malignant effusions as a possible method to enhance cytologic diagnostic sensitivity: an immunocytochemical study of 87 cases</article-title>. <source>Pathol. Patterns</source> <volume>103</volume>, <fpage>206</fpage>&#x2013;<lpage>214</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ajcp/103.2.206</pub-id>, PMID: <pub-id pub-id-type="pmid">7856564</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falsetta</surname> <given-names>M. L.</given-names></name> <name><surname>Klein</surname> <given-names>M. I.</given-names></name> <name><surname>Colonne</surname> <given-names>P. M.</given-names></name> <name><surname>Scott-Anne</surname> <given-names>K.</given-names></name> <name><surname>Gregoire</surname> <given-names>S.</given-names></name> <name><surname>Pai</surname> <given-names>C. H.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Symbiotic relationship between <italic>Streptococcus mutans</italic> and <italic>Candida albicans</italic> synergizes virulence of plaque bio- films <italic>in vivo</italic></article-title>. <source>Infect. Immun.</source> <volume>82</volume>, <fpage>1968</fpage>&#x2013;<lpage>1981</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00087-14</pub-id>, PMID: <pub-id pub-id-type="pmid">24566629</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname> <given-names>H. C.</given-names></name> <name><surname>Neu</surname> <given-names>T. R.</given-names></name> <name><surname>Wozniak</surname> <given-names>D. J.</given-names></name></person-group> (<year>2007</year>). <article-title>The EPS matrix: the &#x201C;house of biofilm cells&#x201D;</article-title>. <source>J. Bacteriol.</source> <volume>189</volume>, <fpage>7945</fpage>&#x2013;<lpage>7947</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00858-07</pub-id>, PMID: <pub-id pub-id-type="pmid">17675377</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamblin</surname> <given-names>M. R.</given-names></name> <name><surname>Abrahamse</surname> <given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Can light-based approaches overcome antimicrobial resistance?</article-title> <source>Drug Dev. Res.</source> <volume>80</volume>, <fpage>48</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ddr.21453</pub-id>, PMID: <pub-id pub-id-type="pmid">30070718</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname> <given-names>K. J. R.</given-names></name> <name><surname>Carmello</surname> <given-names>J. C.</given-names></name> <name><surname>Jord&#x00E3;o</surname> <given-names>C. C.</given-names></name> <name><surname>Barbugli</surname> <given-names>P. A.</given-names></name> <name><surname>Costa</surname> <given-names>C. A. S.</given-names></name> <name><surname>Mima</surname> <given-names>E. G. O.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Antimicrobial photodynamic therapy in combination with nystatin in the treatment of experimental oral candidiasis induced by <italic>Candida albicans</italic> resistant to fluconazole</article-title>. <source>Pharmaceuticals</source> <volume>12</volume>:<fpage>pii: E140</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ph12030140</pub-id></citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konopka</surname> <given-names>K.</given-names></name> <name><surname>Goslinski</surname> <given-names>T.</given-names></name></person-group> (<year>2007</year>). <article-title>Photodynamic therapy in dentistry</article-title>. <source>J. Dent. Res.</source> <volume>86</volume>, <fpage>694</fpage>&#x2013;<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1177/154405910708600803</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>S.</given-names></name> <name><surname>Kumar</surname> <given-names>A.</given-names></name> <name><surname>Roudbary</surname> <given-names>M.</given-names></name> <name><surname>Mohammadi</surname> <given-names>R.</given-names></name> <name><surname>&#x010C;ern&#x00E1;kov&#x00E1;</surname> <given-names>L.</given-names></name> <name><surname>Rodrigues</surname> <given-names>C. F.</given-names></name></person-group> (<year>2022</year>). <article-title>Overview on the infections related to rare <italic>Candida</italic> species</article-title>. <source>Pathogens</source> <volume>11</volume>:<fpage>963</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens11090963</pub-id>, PMID: <pub-id pub-id-type="pmid">36145394</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lambrechts</surname> <given-names>S. A. G.</given-names></name> <name><surname>Aalders</surname> <given-names>M. C. G.</given-names></name> <name><surname>Van Marle</surname> <given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Mechanistic study of the photodynamic inactivation of <italic>Candida albicans</italic> by cationic porphyrin</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>49</volume>, <fpage>2026</fpage>&#x2013;<lpage>2034</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.49.5.2026-2034.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">15855528</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>T. H.</given-names></name></person-group> (<year>1974</year>). <article-title>Bovine pancreatic deoxyribonuclease D</article-title>. <source>J. Biol. Chem.</source> <volume>249</volume>, <fpage>2354</fpage>&#x2013;<lpage>2356</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(19)42737-3</pub-id></citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname> <given-names>C. I. V.</given-names></name> <name><surname>Rinaldi</surname> <given-names>T. B.</given-names></name> <name><surname>Christiano</surname> <given-names>C. M. S.</given-names></name> <name><surname>De Sales</surname> <given-names>L. L.</given-names></name> <name><surname>Barbugli</surname> <given-names>P. A.</given-names></name> <name><surname>Klein</surname> <given-names>M. I.</given-names></name></person-group> (<year>2019</year>). <article-title>Dual-species biofilms of <italic>Streptococcus mutans</italic> and <italic>Candida albicans</italic> exhibit more biomass and are mutually beneficial compared with single-species biofilms</article-title>. <source>J. Oral Microbiol.</source> <volume>11</volume>:<fpage>1581520</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20002297.2019.1581520</pub-id>, PMID: <pub-id pub-id-type="pmid">31681463</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname> <given-names>A. E. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Terapia fotodin&#x00E2;mica: princ&#x00ED;pios, potencial de aplica&#x00E7;&#x00E3;o e perspectivas</article-title>. <source>Qu&#x00ED;m Nova</source> <volume>23</volume>, <fpage>237</fpage>&#x2013;<lpage>243</lpage>. doi: <pub-id pub-id-type="doi">10.1590/S0100-40422000000200015</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname> <given-names>M.</given-names></name> <name><surname>Henriques</surname> <given-names>M.</given-names></name> <name><surname>Lopez-Ribot</surname> <given-names>J. L.</given-names></name> <name><surname>Oliveira</surname> <given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Addition of DNase improves the <italic>in vitro</italic> activity of antifungal drugs against <italic>Candida albicans</italic> biofilms</article-title>. <source>Mycoses</source> <volume>55</volume>, <fpage>80</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1439-0507.2011.02047.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21668524</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname> <given-names>M.</given-names></name> <name><surname>Uppuluri</surname> <given-names>P.</given-names></name> <name><surname>Thomas</surname> <given-names>D. P.</given-names></name> <name><surname>Cleary</surname> <given-names>I. A.</given-names></name> <name><surname>Henriques</surname> <given-names>M.</given-names></name> <name><surname>Lopez-Ribot</surname> <given-names>J. L.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Presence of extracellular DNA in the <italic>Candida albicans</italic> biofilm matrix and its contribution to biofilms</article-title>. <source>Mycopathologia</source> <volume>169</volume>, <fpage>323</fpage>&#x2013;<lpage>331</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11046-009-9264-y</pub-id>, PMID: <pub-id pub-id-type="pmid">20012895</pub-id></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>K. F.</given-names></name> <name><surname>Zarnowski</surname> <given-names>R.</given-names></name> <name><surname>Andes</surname> <given-names>D. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Fungal super glue: the biofilm matrix and its composition, assembly, and functions</article-title>. <source>PLoS Pathog.</source> <volume>12</volume>:<fpage>e1005828</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1005828</pub-id>, PMID: <pub-id pub-id-type="pmid">27685086</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulcahy</surname> <given-names>H.</given-names></name> <name><surname>Charron-Mazenod</surname> <given-names>L.</given-names></name> <name><surname>Lewenza</surname> <given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Extracellular DNA chelates cations and induces antibiotic resistance in <italic>Pseudomonas aeruginosa</italic> biofilms</article-title>. <source>PLoS Pathog.</source> <volume>4</volume>:<fpage>e1000213</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1000213</pub-id>, PMID: <pub-id pub-id-type="pmid">19023416</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nett</surname> <given-names>J.</given-names></name> <name><surname>Lincoln</surname> <given-names>L.</given-names></name> <name><surname>Marchillo</surname> <given-names>K.</given-names></name> <name><surname>Massey</surname> <given-names>R.</given-names></name> <name><surname>Holoyda</surname> <given-names>K.</given-names></name> <name><surname>Hoff</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Putative role of beta-1, 3 glucans in <italic>Candida albicans</italic> biofilm resistance</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>51</volume>, <fpage>510</fpage>&#x2013;<lpage>520</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01056-06</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nobile</surname> <given-names>C. J.</given-names></name> <name><surname>Schneider</surname> <given-names>H. A.</given-names></name> <name><surname>Nett</surname> <given-names>J. E.</given-names></name> <name><surname>Sheppard</surname> <given-names>D. C.</given-names></name> <name><surname>Filler</surname> <given-names>S. G.</given-names></name> <name><surname>Andes</surname> <given-names>D. R.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Complementary adhesin function in <italic>C. albicans</italic> biofilm formation</article-title>. <source>Curr. Biol.</source> <volume>18</volume>, <fpage>1017</fpage>&#x2013;<lpage>1024</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cub.2008.06.034</pub-id>, PMID: <pub-id pub-id-type="pmid">18635358</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panariello</surname> <given-names>B. H. D.</given-names></name> <name><surname>Klein</surname> <given-names>M. I.</given-names></name> <name><surname>Alves</surname> <given-names>F.</given-names></name> <name><surname>Pavarina</surname> <given-names>A. C.</given-names></name></person-group> (<year>2019</year>). <article-title>DNase increases the efficacy of antimicrobial photodynamic therapy on <italic>Candida albicans</italic> biofilms</article-title>. <source>Photodiagn. Photodyn. Ther.</source> <volume>27</volume>, <fpage>124</fpage>&#x2013;<lpage>131</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pdpdt.2019.05.038</pub-id>, PMID: <pub-id pub-id-type="pmid">31152877</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perezous</surname> <given-names>L. F.</given-names></name> <name><surname>Flaitz</surname> <given-names>C. M.</given-names></name> <name><surname>Goldschmidt</surname> <given-names>M. E.</given-names></name> <name><surname>Engelmeier</surname> <given-names>R. L.</given-names></name></person-group> (<year>2005</year>). <article-title>Colonization of <italic>Candida species</italic> in denture wearers with emphasis on HIV infection: a literature review</article-title>. <source>J. Prosthet. Dent.</source> <volume>93</volume>, <fpage>288</fpage>&#x2013;<lpage>293</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.prosdent.2004.11.015</pub-id>, PMID: <pub-id pub-id-type="pmid">15775931</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname> <given-names>R.</given-names></name> <name><surname>Sherry</surname> <given-names>L.</given-names></name> <name><surname>Lappin</surname> <given-names>D. F.</given-names></name> <name><surname>Nile</surname> <given-names>C. J.</given-names></name> <name><surname>Smith</surname> <given-names>K.</given-names></name> <name><surname>Williams</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Extracellular DNA release confers heterogeneity in <italic>Candida albicans</italic> biofilm formation</article-title>. <source>BMC Microbiol.</source> <volume>14</volume>:<fpage>303</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12866-014-0303-6</pub-id>, PMID: <pub-id pub-id-type="pmid">25476750</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>K. C.</given-names></name> <name><surname>Mann</surname> <given-names>E. E.</given-names></name> <name><surname>Endres</surname> <given-names>J. L.</given-names></name> <name><surname>Weiss</surname> <given-names>E. C.</given-names></name> <name><surname>Cassat</surname> <given-names>J. E.</given-names></name> <name><surname>Smeltzer</surname> <given-names>M. S.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>The cid a murein hydrolase regulator contributes to DNA release and biofilm development in <italic>Staphylococcus aureus</italic></article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>104</volume>, <fpage>8113</fpage>&#x2013;<lpage>8118</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0610226104</pub-id>, PMID: <pub-id pub-id-type="pmid">17452642</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandai</surname> <given-names>D.</given-names></name> <name><surname>Tabana</surname> <given-names>Y. M.</given-names></name> <name><surname>Ouweini</surname> <given-names>A. E.</given-names></name> <name><surname>Ayodeji</surname> <given-names>I. O.</given-names></name></person-group> (<year>2016</year>). <article-title>Resistance of <italic>Candida albicans</italic> biofilms to drugs and the host immune system</article-title>. <source>Jundishapur J Microbiol.</source> <volume>9</volume>:<fpage>e37385</fpage>. doi: <pub-id pub-id-type="doi">10.5812/jjm.37385</pub-id>, PMID: <pub-id pub-id-type="pmid">28138373</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seneviratne</surname> <given-names>C. J.</given-names></name> <name><surname>Jin</surname> <given-names>L. J.</given-names></name> <name><surname>Samaranayake</surname> <given-names>Y. H.</given-names></name> <name><surname>Samaranayake</surname> <given-names>L. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Cell density and cell aging as factors modulating antifungal resistance of <italic>Candida albicans</italic> biofilms</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>52</volume>, <fpage>3259</fpage>&#x2013;<lpage>3266</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00541-08</pub-id>, PMID: <pub-id pub-id-type="pmid">18625775</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takakura</surname> <given-names>N.</given-names></name> <name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Ishibashi</surname> <given-names>H.</given-names></name> <name><surname>Oshima</surname> <given-names>H.</given-names></name> <name><surname>Uchida</surname> <given-names>K.</given-names></name> <name><surname>Yamaguchi</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush</article-title>. <source>Microbiol. Immunol.</source> <volume>47</volume>, <fpage>321</fpage>&#x2013;<lpage>326</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1348-0421.2003.tb03403.x</pub-id>, PMID: <pub-id pub-id-type="pmid">12825893</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tetz</surname> <given-names>V.</given-names></name> <name><surname>Tetz</surname> <given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Effect of deoxyribonuclease I treatment for dementia in end-stage Alzheimer's disease: a case report</article-title>. <source>J. Med. Case Rep.</source> <volume>10</volume>:<fpage>131</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13256-016-0931-6</pub-id>, PMID: <pub-id pub-id-type="pmid">27234814</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torabi</surname> <given-names>I.</given-names></name> <name><surname>Sharififar</surname> <given-names>F.</given-names></name> <name><surname>Izadi</surname> <given-names>A.</given-names></name> <name><surname>Ayatollahi Mousavi</surname> <given-names>S. A.</given-names></name></person-group> (<year>2022</year>). <article-title>Inhibitory effects of different fractions separated from standardized extract of <italic>Myrtus communis</italic> L. against nystatin-susceptible and nystatin-resistant <italic>Candida albicans</italic> isolated from HIV positive patients</article-title>. <source>Heliyon</source> <volume>8</volume>:<fpage>e09073</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09073</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wartenberg</surname> <given-names>A.</given-names></name> <name><surname>Linde</surname> <given-names>J.</given-names></name> <name><surname>Martin</surname> <given-names>R.</given-names></name> <name><surname>Schreiner</surname> <given-names>M.</given-names></name> <name><surname>Horn</surname> <given-names>F.</given-names></name> <name><surname>Jacobsen</surname> <given-names>I. D.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Microevolution of <italic>Candida albicans</italic> in macrophages restores filamentation in a nonfilamentous mutant</article-title>. <source>PLoS Genet.</source> <volume>10</volume>:<fpage>e1004824</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1004824</pub-id>, PMID: <pub-id pub-id-type="pmid">25474009</pub-id></citation></ref>
</ref-list>
</back>
</article>